GILD241213P107000
- 13.60
- -2.20-13.92%
Gilead Sciences Newsroom
Gilead Sciences Price Target Maintained With a $80.00/Share by Cantor Fitzgerald
Leerink Partners Initiates Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $99
Gilead Sciences Analyst Ratings
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $115
Gilead Sciences (GILD) Receives a Buy From Jefferies
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $105 to $125
Gilead Sciences' Strategic Focus on Lenacapavir and Lifecycle Management Drives Buy Rating
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating
B of A Securities Reinstates Buy on Gilead Sciences, Announces $109 Price Target
Citi Remains a Buy on Gilead Sciences (GILD)
Gilead Sciences Is Maintained at Outperform by Oppenheimer
Gilead Sciences Analyst Ratings
Wells Fargo Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Oppenheimer Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $115
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Legend Biotech (LEGN) and Gilead Sciences (GILD)
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Gilead Sciences Receives 'Buy' Rating Amid Strong HIV Market Position and Promising Future Prospects
Piper Sandler Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
RBC Capital Sticks to Their Hold Rating for Gilead Sciences (GILD)
Gilead Sciences Price Target Raised to $96.00/Share From $70.00 by UBS